Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04626 (
erbB-2
)
5,251
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The expression of
p185erbB2
and p21ras was determined immunohistochemically in normal mucosa, intestinal metaplasia,
dysplasia
and in intestinal and diffuse type carcinoma of the stomach. The positive rates of
p185erbB2
and p21ras in intestinal type were significantly higher than those of diffuse-type carcinoma. The results indicate that there are differences not only in clinical and biologic features, but also in molecular abnormalities between the two types of stomach cancer. Positive staining of cell membrane for
p185erbB2
was observed specifically in intestinal type cancer, but not in the other lesions. Positive expression of
p185erbB2
on the cell membrane appears to be a useful marker in identification of malignant change of gastric mucosa, as well as a late event of gastrocarcinogenesis. The results of in situ hybridization analysis in cancer tissues were consistent with those obtained by immunohistochemistry and demonstrated amplification of erbB2 gene at the mRNA level. No significant difference of p21ras expression was found among intestinal metaplasia,
dysplasia
, and intestinal type carcinoma; therefore, it might not be a specific marker of malignancy in gastric mucosa. Expression of p21ras may be an early event in the development of lesions predisposing to carcinoma.
...
PMID:Expression of p185erbB2 and p21ras in carcinoma, dysplasia, and intestinal metaplasia of the stomach: an immunohistochemical and in situ hybridization study. 791 79
Oral mucosal lichen planus (OMLP) is a well recognized mucosal disease with unknown aetiology. Considerable controversy exists as to whether OMLP is intrinsically premalignant, or if the disorder facilitates the development of oral mucosal squamous cell carcinoma (OMSCC) by external factors. The aim of the present studies was to investigate the expression of c-
erbB-2
protein in the keratinocytes of the initial biopsies of oral mucosal disorders diagnosed as OMLP with no evidence of epithelial
dysplasia
and to compare the results with the expression of c-
erbB-2
protein in subsequent biopsies obtained from the same patients. These results were compared with the findings from another 26 biopsies from patients with OMLP and control groups (patients with
dysplasia
with no evidence of OMLP, patients with OMSCC with no evidence of OMLP and normal oral mucosa). The expression of the c-
erbB-2
protein was evaluated by immunohistochemical staining of the gene product with the avidin-biotin-complex method using both fresh frozen and paraffin-embedded tissue sections. Five of the initial biopsies from patients with OMLP expressed the c-
erbB-2
protein and one did not. None of the OMLP cases that subsequently showed evidence of
dysplasia
expressed the c-
erbB-2
protein and of the OMSCC specimens from the patients with OMLP, 2 were negative and 1 expressed c-
erbB-2
protein. Within the other group of OMLP specimens 3 (3/26) were negative for c-
erbB-2
staining. The specimens from the control groups all expressed the c-
erbB-2
protein. The results indicated the probability of the absence of c-
erbB-2
staining being an indication of a potential for neoplastic transformation in OMLP with dysplastic changes.
...
PMID:Studies of the inflammatory process and malignant potential of oral mucosal lichen planus. 867 40
The occurrence of different components of the cell growth regulation pathway as expressed in experimental skin carcinogenesis in haired carcinogen-sensitive NMRI, in haired carcinogen resistant DBA/2 mice and in hairless SKH/1 mice was studied by morphological and immunohistochemical methods. The results were compared with respect to neoplastic response, number of tumors, tumor behaviour and to the inducing agent (UV irradiation or chemical carcinogen), in order to increase our understanding of specific alterations in neoplastic development caused by extraneous agents and to determine their possible usefulness as indicators of carcinogen exposure. The expression of growth factors (transforming growth factor alpha and epidermal growth factor), growth factor receptors (epidermal growth factor receptor/c-erbB-1 and c-
erbB-2
/neu), cell signalling component c-myc, the nuclear transcription factor Harvey-Ras and the tumor suppressor gene p53, were studied in carcinogen- and UV-induced tumor formation in mouse. The results showed increased oncogene expression as well as growth factor expression in the skin during tumor development appearing early in neoplastic and premalignant conditions and becoming more distinct during neoplastic progression. Efforts to delineate specifically initiated cells prior to the appearance of morphologically detectable alterations including
dysplasia
, papilloma formation and squamous cell carcinomas, were unsuccessful. Increased staining by antibodies to growth factors and oncogenes were also observed in DBA/2 animals resistant to tumor formation. It is concluded that oncogene expression and growth factor protein deposits are associated with carcinogenic effects, partly explaining the mechanism of action of these agents, but the applicability, as such, for the analysis of potential hazardous agents needs further studies.
...
PMID:Oncogenes and growth factors as indicators of carcinogen exposure. 867 68
Oral mucosal lichen planus (OMLP) is a well recognized mucosal disease with unknown etiology. Considerable controversy exists as to whether OMLP is intrinsically premalignant, or if the disorder facilitates the development of oral mucosal squamous cell carcinoma (OMSCC) by external factors. The aim of the present study was to investigate the expression of c-
erbB-2
protein in the keratinocytes of initial biopsies or oral mucosal disorders diagnosed as OMLP with no evidence of epithelial
dysplasia
, and to compare the results with the expression of c-
erbB-2
protein in subsequent biopsies obtained from the same patients. These results were compared with the findings from control groups (patients with
dysplasia
with no evidence of OMLP, patients with OMSCC with no evidence of OMLP and normal oral mucosa). The expression of the c-
erbB-2
protein was evaluated by immunohistochemical staining of the gene product with the avidin-biotin-complex method using paraffin-embedded tissues sections. Five of the initial biopsies from patients with OMLP expressed the c-
erbB-2
protein and one did not. None of the OMLP cases that subsequently showed evidence of
dysplasia
expressed the c-
erbB-2
protein, and of the three OMSCC specimens from the patients with OMLP, two were negative and one expressed c-
erbB-2
protein. The specimens from the control groups all expressed the c-
erbB-2
protein. The results indicated the probability of the absence of c-
erbB-2
staining being an indication of a potential for neoplastic transformation in OMLP with dysplastic changes.
...
PMID:Expression of c-erbB-2 protein in keratinocytes of oral mucosal lichen planus and subsequent squamous cell carcinoma. 883 Oct 62
We sought to determine if an immunohistochemical panel of p53, PCNA, and c-
erbB-2
was a useful biomarker of transformation in Barrett's metaplasia. P53, PCNA, and c-
erbB-2
immunohistochemistry was performed on resected Barrett's specimens selected to show discrete grades of
dysplasia
and then on prospectively obtained biopsies. In resection specimens, p53 was positive in 36% with no
dysplasia
, in 30% with low-grade
dysplasia
, in 85% with high-grade
dysplasia
, and in 90% of adenocarcinomas. While an evaluation of proliferation throughout the specimen did not differ between groups, surface proliferation was significantly higher in high-grade
dysplasia
than in low-grade or no
dysplasia
. All high-grade
dysplasia
specimens were positive for at least one marker, compared to 44% with no or low-grade
dysplasia
.
C-erbB-2
was only seen in 31% with high-grade
dysplasia
and in 10% of adenocarcinomas. Prospectively, the panel had a sensitivity of 100%, a specificity of 81% and an overall accuracy of 83% in identifying patients who developed high-grade
dysplasia
or cancer. Thus, overexpression of p53 occurs early in the malignant transformation of Barrett's and increases with histologic progression, and proliferation at the surface of Barrett's epithelium increases with progressive grades of
dysplasia
. An immunohistochemical panel of p53 and PCNA is a useful biomarker for Barrett's metaplasia.
...
PMID:Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma. 944 Jun 19
Barrett's esophagus, or specialized intestinal metaplasia, is a common condition associated with gastroesophageal reflux and an increased risk for adenocarcinoma of the esophagus and gastric cardia. Currently, clinical surveillance for early detection of adenocarcinoma relies on the histopathological assessment of
dysplasia
. In this review we present data from the published literature, and combine this with results from our own research, to address what is currently known about the environmental factors and the molecular changes thought to be important in the pathogenesis of Barrett's esophagus. The most important and well-characterized molecular changes, preceding the development of
dysplasia
, are alterations in the p53 and
erbB-2
genes and aneuploidy. These molecular changes, as well as environmental influences, such as the quality and quantity of gastroduodenal refluxate, may result in abnormal cell proliferation which in turn promotes further genetic abnormalities and deregulation of cell growth. The identification of molecular changes, in the context of predisposing environmental factors, will enhance our understanding of the malignant progression of Barrett's esophagus leading to more effective surveillance and treatment.
...
PMID:Recent developments in the molecular characterization of Barrett's esophagus. 957 72
Limited information is currently available on chromosomal abnormalities in esophageal adenocarcinoma and associated premalignant lesions. In this study, numeric changes affecting chromosomes 4, 6, 7, 8, 9, 10, 11, 12, 17, 18, X, and Y were analyzed by using fluorescence in situ hybridization (FISH) with chromosome-specific centromere DNA probes in 12 esophageal adenocarcinomas. In addition, TP53 overexpression, measured by immunohistochemistry, and amplification of
HER-2/neu
and C-MYC, detected by FISH, were analyzed within the same tumors. The most common numeric abnormalities detected were gains of chromosomes 12 (8 cases), 6 (7 cases), 7 (7 cases), and 11 (6 cases). The total number of abnormal chromosomes varied from 0 to 10, with an average of 4.6 per case. Overexpression of TP53 was present in 9 of 12 cases. No correlation was noted between the degree of aneusomy and TP53 overexpression. In contrast,
HER-2/neu
amplification was present in two cases, both with large numbers of aneusomic chromosomes. Amplification of C-MYC was detected in only one case that had a moderate number of numeric abnormalities. In a subset of cases in which premalignant lesions were examined, aneusomy was found to be an early change, frequently present in both Barrett's esophagus and dysplastic regions. In contrast, gene amplification and TP53 overexpression were restricted to more advanced areas of
dysplasia
and malignancy. Screening larger cohorts of patients with Barrett's esophagus or
dysplasia
for numeric abnormalities of chromosomes 6, 7, 11, and 12 may determine whether any of these abnormalities are predictive markers of progression to malignancy.
...
PMID:Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. 977 3
Pancreatic intraepithelial neoplasia is only partially defined. Any attempt to establish the diagnostic criteria of early pancreatic carcinoma has been unsuccessful so far. In the present study we investigate expression of
HER-2/neu
in hyperplastic pancreatic duct epithelium. Material included resected pancreatic tissue obtained from 13 patients with pancreatic carcinoma, 11 with chronic pancreatitis, and 11 patients operated on for other reasons (gastric cancer, carcinoma of papilla Vateri). Hyperplasia of pancreatic duct epithelium was scored as: 1. flat mucosal hyperplasia FH, 2. papillary hyperplasia PH, 3. atypical papillary hyperplasia APH, 4. carcinoma in situ CIS. Immunohistochemical expression of
HER-2/neu
was studied with the biotin-streptavidin method. Results were scored as: 1+ barely perceptible light membranous rimming, 2+ light to moderate rimming, 3+ moderate to strong rimming. Expression of
HER-2/neu
paralleled with the hyperplasia grading, in most cases being negative in normal duct epithelium, weak in flat hyperplasia, and moderate to strong in atypical papillary hyperplasia and carcinoma in situ. In conclusion,
HER-2/neu
expression could be used as an additional marker of hyperplasia,
dysplasia
and atypia of pancreatic ductal and ductular epithelium in the process of pancreatic epithelial neoplasia. This could be especially useful in the cytological diagnosis of pancreatic intraepithelial neoplasia.
...
PMID:HER-2/Neu expression as a progression marker in pancreatic intraepithelial neoplasia. 979 11
The pathobiology of precursor lesions leading to invasive pancreatic adenocarcinoma remains a controversial area, but knowledge of the mechanisms of tumorigenesis may lead to possibly earlier detection, prevention, and treatment in the future. We hypothesize that ductal hyperplasia and
dysplasia
of the pancreas represent precursor lesions and are part of a continuous developmental spectrum evolving into ductal adenocarcinoma of the pancreas. To further define this sequence, we studied the immunohistochemical markers
HER-2/neu
, K-ras, and p53 in 15 adenocarcinomas and 15 nonmalignant specimens of the pancreas. The 15 nonmalignant specimens of the pancreas included both normal pancreas and chronic pancreatitis. Overall,
HER-2/neu
was positive in normal ducts, ductal hyperplasia,
dysplasia
, and carcinoma cells in 0 of 30, 11 of 20 (55%), 10 of 15 (67%), and 12 of 15 (80%), respectively, with progressive increase in the intensity of staining; p53 was positive in 1 of 30 (3%), 0 of 20, 3 of 15 (20%), and 13 of 15 (80%), respectively, and K-ras was positive in 1 of 30 (3%), 6 of 20 (30%), 11 of 15 (73%), and 8 of 15% (53%), respectively. These data support the hypothesis that ductal hyperplasia and
dysplasia
of the pancreas represent precursor lesions, and, in a fashion similar to that in colorectal tumorigenesis, pancreatic cancer seems to accumulate progressive genetic alterations.
...
PMID:Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. 1002 38
The purpose of this study is to evaluate the role of keratinocyte growth factor (KGF), transforming growth factor-alpha (TGF-alpha), and their receptors in altered renal growth caused by complete ureteral obstruction in the developing kidney. Neonatal and adult rats underwent complete unilateral ureteral ligation or sham operation. The kidneys were harvested at 1, 5, 10, 20, and 30 days after obstruction. Renal growth and development was assessed by histology and immunohistocytochemical localization of vimentin, cytokeratin and smooth muscle-alpha actin. Cellular proliferation was measured by [3H]thymidine labeling index of all cells. RNase protection assays were used to quantify mRNA encoding for KGF, KGF receptor, TGF-alpha, and
epidermal growth factor (EGF) receptor
. Ureteral obstruction in the developing kidneys resulted in decreased DNA synthesis, rapid parenchymal loss, myofibroblast proliferation in the interstitium, decreased tubular epithelial cells formation, and development of cystic
dysplasia
. In comparison, obstruction in the mature kidneys resulted in transient growth in the medullary ductal cells, parenchymal loss, and myofibroblast proliferation at a later time, lymphocytic infiltration in the interstitium but not cystic
dysplasia
. KGF and KGF receptor mRNA levels were increased in obstructed neonatal kidneys. Similarly, TGF-alpha and EGF receptor mRNA levels were increased. Delayed and more moderate increases in KGF, KGF receptor, and TGF-alpha expression were also seen in the obstructed mature kidneys. Of importance, the amount of EGF receptor mRNA was not increased in the obstructed compared with the contralateral or sham-operated adult kidneys. This study suggests that obstruction alters the normal expression pattern of KGF, TGF-alpha, and their receptors in renal development. These changes may be responsible for the impaired renal growth and altered development seen in ureteral obstruction of the kidneys. Although some changes are similar to those seen in the adult kidney, the increased expression of TGF-alpha and cystic
dysplasia
are unique to neonatal obstruction.
...
PMID:Growth factor expression in the obstructed developing and mature rat kidney. 1006 5
<< Previous
1
2
3
4
5
Next >>